Product Description
FDA approved facility with DMF,stable supplying, competitive price
AI Product Description
*The following content is generated by AI and is for reference only.
Semaglutide is a potent glucagon-like peptide-1 (GLP-1) receptor agonist developed to treat type 2 diabetes and manage obesity. Chemically, its molecular formula is C187H291N45O59, with a molecular weight of approximately 4113.6 g/mol. The substance is identified by the CAS number 910463-68-2. Structurally, it features a modified amino acid sequence derived from native human GLP-1, incorporating a fatty diacid side chain that enables binding to albumin. This modification significantly extends its half-life, allowing for once-weekly subcutaneous administration or daily oral dosing, which greatly enhances patient adherence compared to earlier generation therapies.
Clinically, Semaglutide serves as a cornerstone in metabolic disease management. Under brand names such as Ozempic and Wegovy, it effectively lowers blood glucose levels by stimulating insulin secretion in a glucose-dependent manner while simultaneously suppressing glucagon release. Beyond glycemic control, it promotes significant weight loss by acting on appetite centers in the hypothalamus to induce satiety and slow gastric emptying. Extensive clinical trials have demonstrated its efficacy in reducing cardiovascular events in high-risk patients with type 2 diabetes, establishing it as a critical tool for comprehensive risk reduction. Furthermore, recent approvals highlight its potential for treating obstructive sleep apnea associated with obesity.
The drug is synthesized using advanced solid-phase peptide synthesis techniques, ensuring high purity and stereochemical accuracy. Its mechanism involves mimicking the endogenous hormone GLP-1, thereby activating specific receptors that regulate energy homeostasis. While generally well-tolerated, common side effects may include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Rare but serious risks involve pancreatitis and thyroid C-cell tumors observed in rodent studies. Despite these considerations, Semaglutide represents a transformative advancement in pharmacotherapy, offering a dual benefit of improved metabolic health and sustainable weight management for millions of individuals globally. Ongoing research continues to explore its applications in non-alcoholic steatohepatitis and other metabolic disorders, solidifying its status as a leading therapeutic agent in modern medicine.